Targeting selective activation of M1 for the treatment of Alzheimers disease: Further chemical optimization and pharmacological characterization of the M1 positive allosteric modulator ML169

James C. Tarr*, Mark L. Turlington, Paul R. Reid, Thomas J. Utley, Douglas J. Sheffler, Hyekyung P. Cho, Rebecca Klar, Tristano Pancani, Michael T. Klein, Thomas M. Bridges, Ryan D. Morrison, Anna L. Blobaum, Zixui Xiang, J. Scott Daniels, Colleen M. Niswender, P. Jeffrey Conn, Michael R. Wood, Craig W. Lindsley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Targeting selective activation of M<sub>1</sub> for the treatment of Alzheimers disease: Further chemical optimization and pharmacological characterization of the M<sub>1</sub> positive allosteric modulator ML169'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds